A review on targeted therapies for lung cancer

Abstract

Lung cancer is one of the leading causes of cancer related deaths. The malignancy is marked by a bleak prognosis and poor clinical result, owing primarily to advanced stage at diagnosis, imposing a significant cost on public health worldwide. Lung cancer genomic analysis revealed genetic variety and complexity, as well as multiple targetable oncogenic driver changes. These molecular profiling efforts have enabled the potential of molecularly tailored medicines to be realized. In this review, an insight has been provided on the current landscape of targeted therapy for lung cancer treatment, the obstacles associated with this approach, and tactics that could be used to overcome those challenges.